Blue Earth Diagnostics Announces AxuminTM (Fluciclovine F 18) Presentations at Upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting – Axumin Recently FDA-approved to Detect Recurrent Prostate...Read More ›
Welcome to Blue Earth Diagnostics
Our mission is to transform the clinical management of patients with cancer by developing and delivering innovative molecular imaging technologies to address unmet clinical needs and reliably inform diagnosis and treatment decisions.
Our team is made up of industry leaders and experts in the field of radiopharmaceuticals development and commercialisation.
Blue Earth Diagnostics is funded by Syncona LLP, a subsidiary of the Wellcome Trust, the second largest philanthropic, not-for-profit healthcare foundation in the world.